Patents by Inventor Charles L. Fox, Jr.

Charles L. Fox, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5616338
    Abstract: A method of preparing an infection-resistant medical device comprising one or more matrix-forming polymers selected from the group consisting of biomedical polyurethane, biomedical silicones and biodegradable polymers, and antimicrobial agents, especially a synergistic combination of a silver salt and chlorhexidine (or its salts); also disclosed are medical devices having the synergistic composition therein or compositions thereon.
    Type: Grant
    Filed: April 19, 1991
    Date of Patent: April 1, 1997
    Assignee: Trustees of Columbia University in The City of New York
    Inventors: Charles L. Fox, Jr., Shanta M. Modak, Lester A. Sampath
  • Patent number: 5374432
    Abstract: Topical compositions for use in the treatment of burns and other infection-prone wounds and of ocular infection are provided. These compositions comprise silver or a silver salt, an antibiotic selected from among aminoglycoside antibiotics and quinolone antibiotics, with the proviso that the antibiotic is not norfloxacin; and a sterile carrier, such as water or an ointment base.
    Type: Grant
    Filed: July 28, 1989
    Date of Patent: December 20, 1994
    Assignee: The Trustees of Columbia University of the City of New York
    Inventors: Charles L. Fox, Jr., deceased, by Alan F. Ruf, legal representative, Shanta M. Modak
  • Patent number: 5334588
    Abstract: The present invention relates to methods of inhibiting transmission of Hepatitis B virus using compositions comprising silver sulfadiazine and preferably further comprising a biguanide such as chlorhexidine and/or a detergent such as sodium deoxycholate. It is based, at least in part, on the discovery that silver sulfadiazine alone or in combination with chlorhexidine or sodium deoxycholate was shown to inhibit Hepatitis B virus DNA synthesis. The inhibitory effect of silver sulfadiazine was enhanced by combining silver sulfadiazine with either chlorhexidine or sodium deoxycholate.
    Type: Grant
    Filed: June 4, 1991
    Date of Patent: August 2, 1994
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Charles L. Fox, Jr., deceased, Shanta M. Modak
  • Patent number: 5019096
    Abstract: A method of preparing an infection-resistant medical device comprising one or more matrix-forming polymers selected from the group consisting of biomedical polyurethane, biomedical silicones and biodegradable polymers, and antimicrobial agents, especially a synergistic combination of a silver salt and chlorhexidine (or its salts); also disclosed are medical devices having the synergistic composition therein or compositions thereon.
    Type: Grant
    Filed: October 14, 1988
    Date of Patent: May 28, 1991
    Assignee: Trustees of Columbia University in the City of New York
    Inventors: Charles L. Fox, Jr., Shanta M. Modak, Lester A. Sampath
  • Patent number: 4952411
    Abstract: An inexpensive, easily available and convenient method of inhibiting the transmission of the AIDS virus in humans as a result of sexual intercourse is provided. The method relies upon a dual mode of action of antiviral compositions comprising silver salts, such as silver sulfadiazine, alone or in combination with chlorhexidine or sodium deoxycholate. These composition are effective to reduce the infectivity of the AIDS virus and also kill the causative organisms of many other sexually transmitted diseases (STD). The method of the invention is therefore useful to reduce the immediate risk of AIDS transmission. It also reduces future risk of AIDS transmission by eliminating STD causing organisms which increase the risk of AIDS.
    Type: Grant
    Filed: October 18, 1988
    Date of Patent: August 28, 1990
    Assignee: Trustees of Columbia University in the City of New York
    Inventors: Charles L. Fox, Jr., Shanta M. Modak
  • Patent number: 4612337
    Abstract: An infection-resistant polymeric material, such as polytetrafluoroethylene, for use on or within a human or animal body, for example, in the form of a vascular graft, can be prepared by an improved method which comprises the following sequence of steps: (a) soaking a polymeric material with a solution of an antimicrobial agent, such as sodium sulfadiazine, oxacillin dissolved in an organic solvent therefor, such as an ethanol/chloroform mixture, (b) soaking the polymeric material with an organic solvent, such as ethanol, for a metal salt; and (c) resoaking the polymeric material with the solution of the antimicrobial agent dissolved in the organic solvent therefor. The polymeric material is dried after each soaking step. Preferably, in the intermediate soaking step (b) the organic solvent contains a metal salt, such as silver nitrate, dissolved therein, so as to form in situ the metal salt of the antimicrobial agent, such as silver sulfadiazine.
    Type: Grant
    Filed: May 30, 1985
    Date of Patent: September 16, 1986
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Charles L. Fox, Jr., Shanta M. Modak
  • Patent number: 4599226
    Abstract: Animal tissue and the like having silver sulfadiazine incorporated therein is useful as a covering for burns and/or wounds. The silver sulfadiazine is incorporated in the tissue by soaking the tissue in an ammoniacal silver sulfadiazine solution or suspension. When the silver sulfadiazine is so incorporated in the tissue via an ammonium solution, more silver is found to be present than would normally be expected and the effectiveness of the thus treated tissue as a wound covering increases.
    Type: Grant
    Filed: March 1, 1984
    Date of Patent: July 8, 1986
    Assignee: Genetic Laboratories, Inc.
    Inventors: Charles L. Fox, Jr., Shanta M. Modak, Paul Fox
  • Patent number: 4581028
    Abstract: Infection-resistant materials, and methods of preparing same, suitable for use within the interior of a human or animal body in such forms as vascular grafts prostheses, or other implanted devices. The material is rendered infection-resistant by incorporating therein antimicrobial agents, such as metal salts of sulfonamides and other antimicrobials or antibacterials, such as piperacillin. In particular illustrative embodiments, silver sulfadiazine is complexed by novel techniques with natural or synthetic polymeric materials such as silk, polyester (e.g., Dacron), polyurethane, polytetrafluoroethylene, or silicone-based material, to provide long-term prevention of infections which may otherwise result during, or after, surgery or implantation of a device.
    Type: Grant
    Filed: April 30, 1984
    Date of Patent: April 8, 1986
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Charles L. Fox, Jr., Shanta Modak, Keith Reemtsma
  • Patent number: 4579731
    Abstract: A protective skin matrix is provided which is particularly suited for the protection of burned or wounded patients. The matrix may be either cured, applied in sheets, or painted or sprayed directly onto the burned or wounded patient. The protective skin matrix includes polyvinylpyrrolidone, polyvinylalcohol, and glycerol.
    Type: Grant
    Filed: June 19, 1984
    Date of Patent: April 1, 1986
    Assignee: Key Pharmaceuticals, Inc.
    Inventors: Charles L. Fox, Jr., Alec D. Keith, Wallace Snipes
  • Patent number: 4563485
    Abstract: Infection-resistant materials, and methods of preparing same, suitable for use within the interior of a human or animal body in such forms as vascular grafts prostheses, or other implanted devices. The material is rendered infection-resistant by incorporating therein antimicrobial agents, such as nalidixic acid derivatives or metal salts of nalidixic acid derivatives. In particular illustrative embodiments, silver norfloxacin and silver pefloxacin, are complexed with natural or synthetic polymeric materials such as silk, polyester (e.g., Dacron), polyurethane, polytetrafluoroethylene, or silicone-based material, to provide long-term prevention of infections which may otherwise result during or after surgery or implantation of a device.
    Type: Grant
    Filed: April 30, 1984
    Date of Patent: January 7, 1986
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Charles L. Fox, Jr., Shanta Modak, Keith Reemtsma
  • Patent number: 4559223
    Abstract: This invention discloses compositions useful as dentifrices or oral medicaments and capable of inhibiting microbial mouth infections. The compositions contain an effectiveamount of silver and/or zinc sulfadiazine and a suitable carrier. By inhibiting microbial mouth infections, these compositions reduce or eliminate dental caries, plaque formation, gingival destruction, bone and tooth loss. The compositions of this invention may be in the form of liquids such as mouthwashes, pastes such as toothpastes or solids such as chewing gums or coated dental tapes or flosses.
    Type: Grant
    Filed: December 6, 1984
    Date of Patent: December 17, 1985
    Assignee: Daltex Medical Sciences, Inc.
    Inventor: Charles L. Fox, Jr.
  • Patent number: 4535078
    Abstract: An antibacterial composition useful in burn therapy comprises silver sulfadiazine, sodium piperacillin and a physiologically acceptable carrier.
    Type: Grant
    Filed: April 6, 1984
    Date of Patent: August 13, 1985
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Charles L. Fox, Jr., Shanta M. Modak
  • Patent number: 4522819
    Abstract: 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid and metal salts thereof wherein the metal moiety is selected from the group consisting of silver, zinc, cerium and cobalt are useful in the treatment of burns. These compounds may be applied to the affected surface of a burn victim either directly or as part of a composition together with a physiologically acceptable carrier, such as a water-dispersible, hydrophilic carrier.
    Type: Grant
    Filed: June 23, 1982
    Date of Patent: June 11, 1985
    Assignee: Norwich Eaton Pharmaceuticals, Inc.
    Inventors: Charles L. Fox, Jr., Shanta M. Modak
  • Patent number: 4446124
    Abstract: Animal tissue and the like having silver sulfadiazine incorporated therein is useful as a covering for burns and/or wounds. The silver sulfadiazine is incorporated in the tissue by soaking the tissue in an ammoniacal silver sulfadiazine solution or suspension. When the silver sulfadiazine is so incorporated in the tissue via an ammonium solution, more silver is found to be present than would normally be expected and the effectiveness of the thus treated tissue as a wound covering increases.
    Type: Grant
    Filed: March 31, 1983
    Date of Patent: May 1, 1984
    Inventors: Charles L. Fox, Jr., Shanta M. Modak, Paul Fox
  • Patent number: 4404197
    Abstract: Compositions which include 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid or its metal salts, e.g., silver, zinc, cobalt or cerium salts, and silver sulfadiazine are effective in the treatment of burns. Of special interest are compositions containing silver sulfadiazine and the silver salt of the above-identified quinoline carboxylic acid, wherein even though each compound is present in a concentration which would be ineffective if either compound were present alone, the resulting compositions are effective. The compositions of this invention may be applied to the affected surface of a burn victim either directly or in combination with a physiologically acceptable carrier, such as a water-dispersible, hydrophilic carrier.
    Type: Grant
    Filed: May 15, 1981
    Date of Patent: September 13, 1983
    Inventors: Charles L. Fox, Jr., Shanta M. Modak
  • Patent number: 4308255
    Abstract: A balanced oncotic pressure fluid suitable as a dialysate in the treatment of patients suffering from loss of kidney function. The solution comprises on the basis of 1 liter of solution about 200-300 mEq sodium, about 145-215 mEq chloride, about 55-85 mEq bicarbonate or acetate or lactate, and about 2-10% by weight dextran, the ratio of sodium to chloride being about 1.4:1. An example of the above solution contains about 224 mEq sodium, about 164 mEq chloride, about 72 mEq acetate, about 6% by weight dextran, about 2% dextrose, about 7 mg zinc gluconate, about 2 mEq potassium, about 3 mEq calcium, and about 2 mEq magnesium.
    Type: Grant
    Filed: March 24, 1980
    Date of Patent: December 29, 1981
    Assignee: Haemophor Corporation
    Inventors: Ghen M. G. Raj, Charles L. Fox, Jr.
  • Patent number: 4262018
    Abstract: Zinc and cerium salts of known oral hypoglycemic agents, particularly sulfonylureas, are effective in lowering elevated blood sugar levels, such as are associated with diabetes.
    Type: Grant
    Filed: May 29, 1979
    Date of Patent: April 14, 1981
    Assignee: Research Corporation
    Inventor: Charles L. Fox, Jr.
  • Patent number: 4195094
    Abstract: Zinc and cerium salts of known oral hypoglycemic agents, particularly sulfonylureas, are effective in lowering elevated blood sugar levels, such as are associated with diabetes.
    Type: Grant
    Filed: December 23, 1977
    Date of Patent: March 25, 1980
    Assignee: Research Corporation
    Inventor: Charles L. Fox, Jr.
  • Patent number: 4078058
    Abstract: Cerium sulfadiazine and compositions containing a cerium sulfadiazine, particularly cerous sulfadiazine [Ce(SD).sub.3 ] wherein SD represents the sulfadiazine moiety, have been found to be useful in the treatment of burns. Cerous sulfadiazine is prepared by reacting an aqueous solution of sodium sulfadiazine with an aqueous solution of a cerous salt, such as cerous nitrate or cerous chloride. The resulting cerous sulfadiazine is formed as a white precipitate. The precipitated cerous sulfadiazine, such as made by reacting cerous nitrate with sodium sulfadiazine, upon washing and drying has a melting point of 248.degree.-255.degree. C.
    Type: Grant
    Filed: July 13, 1976
    Date of Patent: March 7, 1978
    Assignee: Research Corporation
    Inventor: Charles L. Fox, Jr.
  • Patent number: 4049802
    Abstract: Zinc is essential in the complex process of wound healing. Zinc sulfadiazine promotes wound healing and controls infection. When taken into the body, such as by topical application to a wound surface, zinc sulfadiazine dissolves and its dissociation achieves a replacement of zinc lost in the body fluids, such as in the urine, after thermal or other trauma. Although both zinc sulfadiazine and silver sulfadiazine each effectively controls infection and enhances healing in burn wounds, the combination of zinc sulfadiazine and silver sulfadiazine, particularly in a single medicament, possesses enhanced efficacy.
    Type: Grant
    Filed: March 19, 1975
    Date of Patent: September 20, 1977
    Assignee: Research Corporation
    Inventor: Charles L. Fox, Jr.